Search research articles
Contact Us
Filters
Showing results (31-40 of 61) with videos related to
Page
of 7
Sort By:
Cell Reports
|
October 7, 2015
Principles Governing A-to-I RNA Editing in the Breast Cancer Transcriptome
Debora Fumagalli, David Gacquer, Françoise Rothé, et al.
BMC Medicine
|
August 4, 2015
Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer
Amir Sonnenblick, Sylvain Brohée, Debora Fumagalli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 10, 2012
Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value
Patrick G Gavin, Linda H Colangelo, Debora Fumagalli, et al.
NPJ Breast Cancer
|
July 8, 2017
The AURORA pilot study for molecular screening of patients with advanced breast cancer-a study of the breast international group
Marion Maetens, David Brown, Alexandre Irrthum, et al.
JNCI Cancer Spectrum
|
November 26, 2020
Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831
Katherine L Pogue-Geile, Nan Song, Daniel J Serie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 29, 2021
Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial
David Venet, Mattia Rediti, Marion Maetens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 5, 2017
Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial
Amir Sonnenblick, Dominique Agbor-Tarh, Ian Bradbury, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 21, 2022
Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial
Richard D Gelber, Xin V Wang, Bernard F Cole, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 22, 2021
Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis
Sara Pizzamiglio, Chiara Maura Ciniselli, Tiziana Triulzi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 14, 2019
Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial
Françoise Rothé, Maria Joao Silva, David Venet, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 61) with videos related to
Sort By:
Page
of 7
Cell Reports
|
October 7, 2015
Principles Governing A-to-I RNA Editing in the Breast Cancer Transcriptome
Debora Fumagalli, David Gacquer, Françoise Rothé, et al.
BMC Medicine
|
August 4, 2015
Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer
Amir Sonnenblick, Sylvain Brohée, Debora Fumagalli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 10, 2012
Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value
Patrick G Gavin, Linda H Colangelo, Debora Fumagalli, et al.
NPJ Breast Cancer
|
July 8, 2017
The AURORA pilot study for molecular screening of patients with advanced breast cancer-a study of the breast international group
Marion Maetens, David Brown, Alexandre Irrthum, et al.
JNCI Cancer Spectrum
|
November 26, 2020
Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831
Katherine L Pogue-Geile, Nan Song, Daniel J Serie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 29, 2021
Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial
David Venet, Mattia Rediti, Marion Maetens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 5, 2017
Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial
Amir Sonnenblick, Dominique Agbor-Tarh, Ian Bradbury, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 21, 2022
Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial
Richard D Gelber, Xin V Wang, Bernard F Cole, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 22, 2021
Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis
Sara Pizzamiglio, Chiara Maura Ciniselli, Tiziana Triulzi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 14, 2019
Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial
Françoise Rothé, Maria Joao Silva, David Venet, et al.
Page
of 7